Fig. 1From: Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trialASPECT-NP study design [20]. h hour, ITT intent-to-treat, LRT lower respiratory tract, q8h every 8 h, TOC test-of-cure, SOFA Sequential Organ Failure Assessment, VABP ventilator-associated bacterial pneumonia, vHABP ventilated hospital-acquired bacterial pneumoniaBack to article page